| Identification | Back Directory | [Name]
Satraplatin | [CAS]
129580-63-8 | [Synonyms]
JM 216
C081294
BMY 45594
BMS 182751
SATRAPLATIN
Satraplatin(JM216)
BMS-182751;BMY-45594;JM-216
bis(acetato-o)amminedichloro(cyclohexanamine)-pt
Bis-acetatoamminedichlorocyclohexylamine platinum(iv)
(OC-6-43)-bis(acetato)amminedichloro(cyclohexylamine)platinum
Cis-dichloro-trans-diacetoxyl-cis-amino, cyclohexaneplatinum (IV)
Platinum, bis(acetato-o)amminedichloro(cyclohexanamine)-, (oc-6-43)-
platinum (lv) cis-dichloro-trans-bis(acetato-o)ammine(cyclohexanamine) | [Molecular Formula]
C10H22Cl2N2O4Pt | [MDL Number]
MFCD00871429 | [MOL File]
129580-63-8.mol | [Molecular Weight]
500.28 |
| Hazard Information | Back Directory | [Uses]
Antineoplastic. | [Definition]
ChEBI: A platinum coordination entity that consists of a central platunum atom bound to chloro (x2), acetate (x2), amino, and cyclohexylamino groups. Used for treatment of advanced prostate cancer. | [Pharmaceutical Applications]
Satraplatin (JM216, cis,trans,cis-[PtCl2(OAc)2(NH3)(C6H5NH2)]) is a Pt(IV) or Pt4+ complex, which is
active by oral administration, as it is more hydrophobic than cisplatin. This form of administration is very
attractive because of the convenience and freedom it provides to the patient. Satraplatin also has a milder toxicity
profile and is shows no cross-resistance with cisplatin. Satraplatin in combination with prednisone has
completed phase III clinical trials against hormone-refractory prostate cancer. The results were very encouraging,
but the overall survival rate did not improve significantly enough. As a result, the fast-track approval
of the FDA was not granted.
Structurally, satraplatin consists of a Pt(IV) centre, which is coordinated by six ligands forming a close to octahedral geometry. In general, octahedral Pt(IV) complexes (low-spin d6) are much more kinetically inert than square planar Pt(II) complexes. | [Clinical Use]
This newest organometallic agent currently is in clinical trials as a second-line agent for the treatment of hormone-refractory prostate cancer . There is hope that it also will find value in ovarian cancer and small cell lung cancer. | [Side effects]
As with other organoplatinum complexes, the diaquo form is active. At this early stage, the toxicity profile appears to be mild, with dose-related myelosuppression, particularly neutropenia and thrombocytopenia, being the major use-limiting side effect. | [Metabolism]
Unlike the square-planar Pt(II) complexes currently on the market, it is active by the oral route. It is metabolized quickly in whole blood, producing up to six metabolites. The major metabolite is the desacetoxy analogue. | [storage]
Store at -20°C |
|
|